Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FRAME-001 Personalized Tumor Neoantigen Vaccine in Advanced NSCLC
2021-003166-12Phase 2Terminated
- Sponsor
- Frame Cancer Therapeutics
- Start
- Jan 2022
- Modality
- Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of FRAME-001 in non-small cell lung cancer (NSCLC), sponsored by Frame Cancer Therapeutics. Primary endpoint: FRAME-001-specific immune responses in peripheral blood. Started Jan 2022; status: terminated.
02
Drugs
FRAME-001
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2021-003166-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003166-12.